On June 10, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after at least two prior…
On May 28, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID, Celgene Corporation) in combination with rituximab (RITUXAN, Genentech, Inc.) for the treatment of adult patients with relapsed or refractory follicular…
On May 24, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. The approval was…
New York (May 15, 2019) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of venetoclax (VENCLEXTA, AbbVie Inc. and Genentech, Inc.) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic…
New York, NY –The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) in combination with obinutuzumab (GAZYVA) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This…
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has expanded the approved use of brentuximab vedotin (ADCETRIS) injection in combination with chemotherapy for adult patients with previously untreated systemic anaplastic large cell lymphoma (ALCL) and…
The Lymphoma Research Foundation extends its heartfelt condolences to the family, loved ones and colleagues of Paul Allen. Mr. Allen contributed greatly to science, philanthropy and business and was committed to improving people’s lives and strengthening communities around the world. Our…
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of duvelisib (COPIKTRA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after…
New York, NY (August 27, 2018) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) plus rituximab (RITUXAN) for the treatment of adult patients with Waldenström macroglobulinemia (WM). This approval represents the…